Introduction
============

Intrahepatic cholangiocarcinoma (ICC) is the second most common biliary malignancy and accounts for 5% to 10% of primary liver carcinomas \[[@b1-crt-2017-106]\]. A rapidly increasing incidence of ICC has been reported over the last few decades \[[@b2-crt-2017-106]\]. Operation is the only potentially curative therapeutic measure for patients with ICC. Unfortunately, less than 30% of ICC patients are not able to have an operation at the initial diagnosis due to a lack of appropriate markers for early diagnosis. In addition, even after curative hepatectomy, the outcome remains grim, with the 5-year survival rate ranging from 20% to 40% \[[@b3-crt-2017-106],[@b4-crt-2017-106]\]. The poor prognosis after surgery is mainly due to tumor recurrence and metastasis \[[@b5-crt-2017-106]\]. Therefore, it is of great significance to screen for effective markers to identify ICC patients at a high risk of recurrence or metastases, thus providing timely and effective therapeutic treatment to improve the clinical outcomes.

As a routine liver function test index, aspartate aminotransferase (AST) reflects the damage of the liver. It is commonly used to assess the severity of various liver diseases \[[@b6-crt-2017-106]\]. Recently, studies have reported that prognostic indexes based on inflammatory cells such as neutrophils and lymphocytes can reflect the survival of various malignancies \[[@b7-crt-2017-106],[@b8-crt-2017-106]\], with aspartate aminotransferase to neutrophil ratio index (ANRI) as one of them. For example, elevated ANRI was found to be significantly correlated with a poorer outcome in patients with hepatocellular carcinoma \[[@b9-crt-2017-106]\].

The relation between ANRI and the prognosis of ICC patients after hepatic resection has not been reported. In the present study, we aim to evaluate the predictive value of preoperative ANRI on both the overall survival (OS) and disease-free survival (DFS) of ICC patients after hepatectomy.

Materials and Methods
=====================

1. Patients
-----------

A total of 184 newly diagnosed ICC patients treated with hepatectomy at the First Affiliated Hospital, Sun Yat-sen University between April 2004 and September 2015 were included. All specimens were histologically proven to be ICC after surgery. Informed consent was obtained, and procedures were carried out with prior approval of the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Routine assessment was performed for all patients within 7 days before surgery, including physical examination, complete hematologic and biochemistry profiles, chest X-ray, abdominal ultrasonography, and contrast-enhanced computed tomography (CT) scans or magnetic resonance imaging.

All patients were \> 18 years of age, with complete clinical and laboratory data. No patients had any coexistent hematological disorders or known active infection before treatment. In addition, patients with preoperative anti-tumor treatment, such as chemotherapy or percutaneous ablation, were excluded from this study.

2. Treatment and follow-up
--------------------------

Surgical strategies were decided by a multidisciplinary team meeting. Combined operations such as biliary-intestinal anastomosis were applied when needed. Postoperative follow-up of all 184 patients was regularly performed according to institutional practice, including serum carbohydrate antigen 19-9 (CA19-9), α-fetoprotein (AFP), carcinoembryonic antigen (CEA), abdominal ultrasound, and chest X-ray every 3 months, and contrast-enhanced CT every 6 months. Recurrence was defined as the emergence of clinical, radiological, and/or pathological diagnosis (tissues obtained by ultrasound-guided fine-needle aspiration) of the tumor. Patients with confirmed recurrence of ICC received salvage treatments, such as repeated hepatectomy, percutaneous ablation or chemotherapy. DFS was calculated from the date of operation to the date of recurrence. OS was calculated from the date of operation to the date of death or last follow-up.

3. Statistical analysis
-----------------------

The best cut-off value of ANRI was determined by a receiver operating characteristic (ROC) curve. The difference between categorical variables was test by the Pearson chisquare test (two-tailed). Pearson bivariate correlate analyses (two-tailed) were used to compare the correlations of these categorical variables. Non-normally distributed numerical variables were tested using a Mann-Whitney U test. Survival curves (including stratified analysis) were plotted using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model (Backward stepwise) was used to determine the independent prognostic factors based on variables selected on univariate analysis (with p \< 0.05), and the results were expressed as a hazard ratio with a 95% confidence interval (95% CI). There are significant differences when p-values are \< 0.05, using two-tailed tests. Statistical analyses performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY).

Results
=======

1. Demographic and clinicopathological characteristics
------------------------------------------------------

This study included 99 males (53.8%) and 85 females (46.2%). The mean age of the cohort was 56.0 years (range, 24 to 82 years). There were 163 patients (88.6%) who developed tumor recurrence and 152 patients (82.6%) died during the observation period. The mean tumor size was 6.0 cm (range, 1.0 to 20.0 cm) at the greatest diameter. Elevated serum CA19-9 (≥ 35.0 U/mL) was observed in 119 patients (64.7%), and 63 patients (34.2%) had multiple tumor masses. Serum hepatitis B surface antigen (HBsAg) was positive in 51 patients (27.7%), and cirrhosis existed in 46 patients (25.0%). Additionally, 28 patients had a past history of surgery due to hepatolithiasis. Tumor differentiation was defined according to the World Health Organization classification of tumors of the digestive system 2010 \[[@b10-crt-2017-106]\]. Tumors from 125 patients (67.9%) were well moderated, and those from 59 patients (32.1%) were poorly differentiated. In addition, 79 patients (42.9%) were in TNM stage I+II and 105 patients (57.1%) were in TNM stage III+IV ([Table 1](#t1-crt-2017-106){ref-type="table"}).

2. Determination of an ANRI cut-off value
-----------------------------------------

ANRI was calculated using the formula: ANRI=(AST value/neutrophil count)×10^9^/U. According to ROC curve analysis, the optimal cut-off value of ANRI was 6.7 for predicting postoperative prognosis. The area under ROC curve for survival status was 0.703, with a 95% CI of 0.604-0.802 (p \< 0.001) ([Fig. 1A](#f1-crt-2017-106){ref-type="fig"}). The maximal Youden Index (sensitivity+ specifcity--1) showed a sensitivity of 81.3% and a specificity of 57.9%. Subsequently, all patients were divided into two groups: a high ANRI group (\> 6.7, n=90) and low ANRI group (≤ 6.7, n=94).

3. Relationship between ANRI and clinicopathological characteristics in ICC
---------------------------------------------------------------------------

The relationships between preoperative ANRI and clinicopathological variables were summarized in [Table 1](#t1-crt-2017-106){ref-type="table"}. The results showed that preoperative ANRI was related to tumor size (χ^2^=4.980, p=0.026), tumor recurrence (χ^2^=12.848, p \< 0.001), white blood cell (χ^2^=21.971, p \< 0.001), neutrophil count (χ^2^=26.679, p \< 0.001), AST (χ^2^=48.122, p \< 0.001), and alanine transaminase (χ^2^=18.952, p \< 0.001). However, there were no significance associations of ANRI with age, sex, cirrhosis, HBsAg, tumor number, tumor differentiation, lymph node metastasis, vascular invasion, TNM stage, and CA19-9 (all p \> 0.05) ([Table 1](#t1-crt-2017-106){ref-type="table"}).

4. Distribution of ANRI according to tumor size, recurrence, and lymph node metastasis
--------------------------------------------------------------------------------------

The results indicated that preoperative ANRI in ICC patients with a tumor size \> 6 cm was markedly lower than those with a tumor size ≤ 6 cm (p=0.003) ([Fig. 1B](#f1-crt-2017-106){ref-type="fig"}). This tendency also existed in ICC patients with tumor recurrence and lymph node metastasis, compared to those without tumor recurrence and lymph node metastasis (p=0.003 and p=0.026, respectively) ([Fig. 1B](#f1-crt-2017-106){ref-type="fig"}).

5. Prognostic factors for ICC
-----------------------------

In this study, the 1-year and 3-year OS rates of all patients were 37.0% and 13.0%, respectively. The 1-year and 3-year DFS rates were 22.3% and 11.3%, respectively. The median OS and DFS times were 10.0 and 4.0 months, respectively. Univariate analysis and the multivariate Cox's proportional hazard regression model analysis were performed to identify the risk factors of prognosis. Univariate analysis revealed that preoperative ANRI (p=0.004), sex (p=0.014), tumor number (p=0.003), tumor size (p=0.006), tumor differentiation (p=0.002), TNM stage (p=0.002), resection margin (p=0.001), lymph node metastasis (p=0.003), neutrophil (p=0.034), and CEA (p=0.008) were prognostic factors for OS among the ICC cohort ([Table 2](#t2-crt-2017-106){ref-type="table"}). The preoperative ANRI (p=0.003), sex (p=0.035), tumor number (p=0.001), tumor size (p \< 0.001), tumor differentiation (p=0.020), TNM stage (p=0.003), resection margin (p=0.001), lymph node metastasis (p=0.011), intraoperative blood loss (p=0.024), neutrophil (p=0.031), and CEA (p=0.001) were prognostic predictors for DFS in patients with ICC after hepatectomy ([Table 2](#t2-crt-2017-106){ref-type="table"}). After multivariate analysis, the results indicated that ANRI, tumor number, tumor size, tumor differentiation, and resection margin were significant independent prognostic markers of OS (all p \< 0.05), while ANRI, tumor size, differentiation, and resection margin were independent predictors of DFS (all p \< 0.05) ([Table 3](#t3-crt-2017-106){ref-type="table"}).

6. OS and DFS according to ANRI
-------------------------------

Kaplan-Meier method was performed to clarify the influence of preoperative ANRI on patient survival. The results indicated that the 1-year and 3-year OS rates of the ANRI ≤ 6.7 group were markedly lower than those of the ANRI \> 6.7 group (30.9% and 3.8% vs. 43.3% and 26.6%, respectively, p=0.004) ([Table 2](#t2-crt-2017-106){ref-type="table"}, [Fig. 2A](#f2-crt-2017-106){ref-type="fig"}), while the 1-year and 3-year DFS rates of the ANRI ≤ 6.7 group were also significantly lower than those of the ANRI \> 6.7 group (13.8% and 3.2% vs. 31.1% and 20.9%, respectively, p=0.003) ([Table 2](#t2-crt-2017-106){ref-type="table"}, [Fig. 2B](#f2-crt-2017-106){ref-type="fig"}). Therefore, a low preoperative ANRI level was correlated with a poor survival outcome in patients with ICC after hepatectomy.

7. Prognostic values of ANRI in various subgroups of ICC
--------------------------------------------------------

The research above confirmed that preoperative ANRI ≤ 6.7 was significantly correlated with lower OS and DFS rates in patients with ICC. We further evaluated the prognostic significance of preoperative ANRI in various subgroups of ICC patients. The data showed that preoperative ANRI was a prognostic predictor for OS (p=0.004) and DFS (p=0.004) in ICC patients with TNM stage of I+II ([Fig. 3A](#f3-crt-2017-106){ref-type="fig"} and [B](#f3-crt-2017-106){ref-type="fig"}). This predictive value of declined preoperative ANRI for poorer OS and DFS also existed in the subgroups of single tumor, without lymph node metastasis, R0 resection margin, without biliary-intestinal anastomosis, Child-Pugh Class A, serum HBsAg negative, AFP ≤ 200.0 μg/L, and CA19-9 \> 35.0 U/mL (all p \< 0.05) ([Figs. 3C](#f3-crt-2017-106){ref-type="fig"}-[F](#f3-crt-2017-106){ref-type="fig"}, [4](#f4-crt-2017-106){ref-type="fig"}, [5](#f5-crt-2017-106){ref-type="fig"}). These results suggested that preoperative ANRI was a sensitive parameter to predict the survival of ICC patients after hepatic resection, especially in various subgroups of patients with ICC whose prognosis is difficult to estimate.

Discussion
==========

Tumor recurrence or metastasis severely influenced the prognosis of ICC after hepatectomy, a simple and effective method to identify surgical patients at high risk of recurrence is of great value for clinical work. In this study, we find ANRI to be a reliable non-invasive prognostic biomarker for ICC patients.

Inflammation and inflammatory biomarkers play a central role in tumor progression, associating with tumor proliferation, survival and migration \[[@b11-crt-2017-106]\]. Neutrophils are a critical component of the systemic inflammatory response and several studies have verified that the neutrophil count or neutrophil-lymphocyte ratio index were predictors of prognosis in various malignancies \[[@b7-crt-2017-106],[@b12-crt-2017-106],[@b13-crt-2017-106]\]. In the present study, we found that preoperative declined ANRI (≤ 6.7) showed earlier recurrence and poorer OS in ICC patients after hepatic resection. Additionally, our data suggested that ANRI was negatively related to tumor size and recurrence. These results indicated that ANRI could reflect not only the hepatocyte injury but also the tumor burden and disease development. Both univariate analysis and multivariate analysis showed that tumor size \> 6 cm, poor differentiation, R1 resection margin and declined ANRI were independent risk factors for both poor OS and DFS of ICC patients after hepatectomy.

The results of further analysis showed that preoperative ANRI had a significant predictive value for both OS and DFS in ICC patients with TNM stage I+II, meaning that ANRI could predict recurrence of early ICC. As one of the risk factors of ICC, chronic hepatitis B virus infection impacted prognosis of ICC following resection \[[@b14-crt-2017-106]\]. It is usually more difficult to estimate the survival of serum HBsAg-negative patients. However, the data in this study indicated that ANRI shows its markedly prognostic value in those ICC patients. Furthermore, in subgroups with a single tumor, without lymph node metastasis, a R0 resection margin, without biliary-intestinal anastomosis, Child-Pugh Class A, an AFP ≤ 200.0 μg/L and an elevated CA19-9 level, preoperative ANRI ≤ 6.7 also shows its significance in predicting poorer OS and DFS.

These results showed that preoperative ANRI is a potential efficient prognostic indicator of survival in patients with ICC after hepatectomy. However, the exact reason for the association between declined preoperative ANRI and poor prognosis is not well understood. Our study showed that preoperative neutrophil count was markedly negatively correlated with ANRI, which means that patients with a lower ANRI have relative neutrophilia. The critical role of neutrophil in systemic inflammation and tumor progression might explain part of this phenomenon. Neutrophils were reported to facilitate tumor cell invasion and migration by secreting immune-reactive substances such as hepatocyte growth factor \[[@b15-crt-2017-106]\] and neutrophil elastase \[[@b16-crt-2017-106]\]. In addition, neutrophils can affect the prognosis of malignancy by directly down-regulating the cellular immunity function of the host \[[@b17-crt-2017-106]\]. ICC cells may recruit more neutrophils to the tumor foci by expressing higher levels of chemokine ligand 5, which amplifies the inflammatory response and promotes ICC metastasis and recurrence \[[@b18-crt-2017-106]\]. Furthermore, increased neutrophils are regarded as an important composition of compartments for circulating vascular endothelial growth factor (VEGF) \[[@b19-crt-2017-106]\]. Patients with lower ANRI have relative neutrophilia and may have a higher level of circulating VEGF. It has been reported that autocrine VEGF/vascular endothelial growth factor receptor 2 signaling promotes growth of ICC cells, and apatinib inhibits anti-apoptotic cell proliferation by suppressing the autocrine VEGF signaling \[[@b20-crt-2017-106]\]. Therefore, apatinib may be considered as a candidate in the treatment of ICC patients with lower preoperative ANRI.

There are some limitations in the present study. First, it is a retrospective study of a single center and the sample size is relatively small. Second, our data is mainly based on ICC patients with predominant hepatitis B virus infection and hepatolithiasis in China. Therefore, the results for application in Western populations with predominant primary sclerosing cholangitis \[[@b21-crt-2017-106]\] or hepatitis C virus infection should be further studied.

In conclusion, our study showed that preoperative declined ANRI is a novel independent indicator for poor prognosis of ICC patients after hepatectomy. ICC patients with preoperative declined ANRI might benefit from close follow up and prophylactic personalized therapy.
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![Receiver operating characteristic (ROC) curve and distribution of preoperative aspartate aminotransferase/neutrophil count ratio index (ANRI) in different intrahepatic cholangiocarcinoma (ICC) subgroups. (A) ROC analysis was performed to determine the optimal cut-off value of ANRI in patients with ICC after hepatectomy (cut-off value=6.7). The area under the ROC curve for survival status was 0.703 (95% confidence interval, 0.604 to 0.802; p \< 0.001), with a sensitivity of 81.3% and a specificity of 57.9%. (B) Comparison of preoperative ANRI in ICC subgroups, stratified by tumor size, recurrence, and lymph node metastasis (LNM). The proportions of ICC patients with declined preoperative ANRI along with tumor size \> 6 cm, recurrence, and with LNM are much higher than those with tumor size ≤ 6 cm, without recurrence, and without LNM, respectively (all p \< 0.05, Mann-Whitney U test). AUC, area under the curve.](crt-2017-106f1){#f1-crt-2017-106}

![Kaplan-Meier survival curves of overall survival (A) and disease-free survival (B) for intrahepatic cholangiocarcinoma patients with aspartate aminotransferase/neutrophil count ratio index (ANRI) \> 6.7 and ANRI ≤ 6.7 in the entire cohort. p-values were obtained by log-rank tests.](crt-2017-106f2){#f2-crt-2017-106}

![Kaplan-Meier survival curves of patients with intrahepatic cholangiocarcinoma after hepatectomy stratified by TNM stage I+II (A, B), single tumor status (C, D), and without lymph node metastasis (E, F). p-values were obtained by log-rank tests. ANRI, aspartate aminotransferase/neutrophil count ratio index.](crt-2017-106f3){#f3-crt-2017-106}

![Kaplan-Meier survival curves of patients with intrahepatic cholangiocarcinoma after hepatectomy stratified by R0 resection margin (A, B), without biliary-intestinal anastomosis (C, D), and Child-Pugh Class A (E, F). p-values were obtained by log-rank tests. ANRI, aspartate aminotransferase/ neutrophil count ratio index.](crt-2017-106f4){#f4-crt-2017-106}

![Kaplan-Meier survival curves of patients with intrahepatic cholangiocarcinoma after hepatectomy stratified by serum hepatitis B surface antigen (HBsAg) negative (A, B), α-fetoprotein (AFP) ≤ 200.0 μg/L (C, D), and carbohydrate antigen 19-9 (CA19-9) \> 35.0 U/mL (E, F). p-values were obtained by log-rank tests. ANRI, aspartate aminotransferase/neutrophil count ratio index.](crt-2017-106f5){#f5-crt-2017-106}

###### 

Relationship between ANRI and clinicopathological characteristics in ICC (n=184)

  Category                                                                        No.   ANRI        χ^2^        r        p-value   
  ------------------------------------------------------------------------------- ----- ----------- ----------- -------- --------- ----------
  Age (yr)                                                                                                                         
   ≤ 60                                                                           117   59 (50.4)   58 (49.6)   0.056    \-        0.813
   \> 60                                                                          67    35 (52.2)   32 (47.8)                      
  Sex                                                                                                                              
   Female                                                                         85    40 (47.1)   45 (52.9)   1.026    \-        0.311
   Male                                                                           99    54 (54.5)   45 (45.5)                      
  Preoperative symptom                                                                                                             
   No                                                                             51    26 (51.0)   25 (49.0)   0.000    \-        0.986
   Yes                                                                            133   68 (51.1)   65 (48.9)                      
  Cirrhosis                                                                                                                        
  No                                                                              138   70 (50.7)   68 (49.3)   0.029    \-        0.865
   Yes                                                                            46    24 (52.2)   22 (47.8)                      
  HBsAg                                                                                                                            
   Negative                                                                       133   67 (50.4)   66 (49.6)   0.097    \-        0.755
   Positive                                                                       51    27 (52.9)   24 (47.1)                      
  Tumor number                                                                                                                     
   Single                                                                         121   60 (49.6)   61 (50.4)   0.318    \-        0.573
   Multiple                                                                       63    34 (54.0)   29 (46.0)                      
  Tumor size (cm)^[a)](#tfn1-crt-2017-106){ref-type="table-fn"}^                                                                   
   ≤ 6                                                                            97    42 (43.3)   55 (56.7)   4.980    --0.165   0.026
   \> 6                                                                           87    52 (59.8)   35 (40.2)                      
  Capsulation                                                                                                                      
   No                                                                             111   58 (52.3)   53 (47.7)   0.152    \-        0.697
   Yes                                                                            73    36 (49.3)   37 (50.7)                      
  Differentiation^[b)](#tfn2-crt-2017-106){ref-type="table-fn"}^                                                                   
   W+M                                                                            125   60 (48.0)   65 (52.0)   1.487    \-        0.223
   P                                                                              59    34 (57.6)   25 (42.4)                      
  Lymph node metastasis                                                                                                            
   No                                                                             111   51 (45.9)   60 (54.1)   2.959    \-        0.085
   Yes                                                                            73    43 (58.9)   30 (41.1)                      
  Vascular invasion                                                                                                                
   No                                                                             174   90 (52.0)   83 (48.0)   1.015    \-        0.314
   Yes                                                                            11    4 (36.4)    7 (63.6)                       
  TNM^[c)](#tfn3-crt-2017-106){ref-type="table-fn"}^                                                                               
   I+II                                                                           79    39 (49.4)   40 (50.6)   0.164    \-        0.686
   III+IV                                                                         105   55 (52.4)   50 (47.6)                      
  Resection margin                                                                                                                 
   R0                                                                             108   60 (55.6)   48 (44.4)   2.089    \-        0.148
   R1                                                                             76    34 (44.7)   42 (55.3)                      
  Biliary-intestinal anastomosis                                                                                                   
   No                                                                             158   83 (52.5)   75 (47.5)   0.934    \-        0.334
   Yes                                                                            26    11 (42.3)   15 (57.7)                      
  Complication                                                                                                                     
   No                                                                             155   79 (51.0)   76 (49.0)   0.006    \-        0.940
   Yes                                                                            29    15 (51.7)   14 (48.3)                      
  Intraoperative blood loss (mL)^[a)](#tfn1-crt-2017-106){ref-type="table-fn"}^                                                    
   ≤ 400                                                                          104   55 (52.9)   49 (47.1)   0.309    \-        0.578
   \> 400                                                                         80    39 (48.8)   41 (51.2)                      
  Recurrence                                                                                                                       
   No                                                                             21    3 (14.3)    18 (85.7)   12.848   --0.264   \< 0.001
   Yes                                                                            163   91 (55.8)   72 (44.2)                      
  WBC (×10^9^/L)                                                                                                                   
   ≤ 10                                                                           148   63 (42.6)   85 (57.4)   21.971   --0.346   \< 0.001
   \> 10                                                                          36    31 (86.1)   5 (13.9)                       
  Neutrophil (×109/L)^[a)](#tfn1-crt-2017-106){ref-type="table-fn"}^                                                               
   ≤ 4.55                                                                         93    30 (32.3)   63 (67.7)   26.679   --0.381   \< 0.001
   \> 4.55                                                                        91    64 (70.3)   27 (29.7)                      
  Platelet (×10^9^/L)                                                                                                              
   ≤ 300                                                                          139   66 (47.5)   73 (52.5)   2.956    \-        0.086
   \> 300                                                                         45    28 (62.2)   17 (37.8)                      
  AST (U/L)                                                                                                                        
   ≤ 37                                                                           133   89 (66.9)   44 (33.1)   48.122   0.511     \< 0.001
   \> 37                                                                          51    5 (9.8)     46 (90.2)                      
  ALT (U/L)                                                                                                                        
   ≤ 80                                                                           158   91 (57.6)   67 (42.4)   18.952   0.321     \< 0.001
   \> 80                                                                          26    3 (11.5)    23 (88.5)                      
  γ-GT (U/L)                                                                                                                       
   ≤ 50                                                                           50    24 (48.0)   26 (52.0)   0.262    \-        0.609
   \> 50                                                                          134   70 (52.2)   64 (47.8)                      
  AFP (μg/L)                                                                                                                       
   ≤ 200                                                                          176   89 (50.6)   87 (49.4)   0.436    \-        0.509
   \> 200                                                                         8     5 (62.5)    3 (37.5)                       
  CEA (μg/L)                                                                                                                       
   ≤ 5.0                                                                          107   53 (49.5)   54 (50.5)   0.247    \-        0.619
   \> 5.0                                                                         77    41 (53.2)   36 (46.8)                      
  CA19-9 (U/mL)                                                                                                                    
   ≤ 35                                                                           65    37 (56.9)   28 (43.1)   1.370    \-        0.242
   \> 35                                                                          119   57 (47.9)   62 (52.1)                      

ANRI, aspartate aminotransferase/neutrophil count ratio index; ICC, intrahepatic cholangiocarcinoma; HBsAg, hepatitis B surface antigen; W+M, well+moderated differentiation; P, poor differentiation; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine transaminase; γ-GT, γ-glutamyl transpeptidase; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

Medians were used for cut-off values,

According to the World Health Organization (WHO) classification of tumors of the digestive system 2010,

Based on seventh edition cancer staging manual of American Joint Committee on Cancer.

###### 

Univariate analyses for prognostic factors of patients with ICC (n=184)

  Category                                                                            No.   OS     p-value   DFS     p-value           
  ----------------------------------------------------------------------------------- ----- ------ --------- ------- --------- ------- ----------
  **Age (yr)**                                                                                                                         
   ≤ 60                                                                               117   34.2   13.4      0.723   20.5      10.9    0.437
   \> 60                                                                              67    41.8   11.2              25.4      11.9    
  **Sex**                                                                                                                              
   Female                                                                             85    47.1   15.6      0.014   30.6      14.6    0.035
   Male                                                                               99    28.3   8.1               15.2      8.5     
  **Preoperative symptom**                                                                                                             
   No                                                                                 51    41.2   16.7      0.464   27.5      10.5    0.575
   Yes                                                                                133   35.3   10.1              20.3      11.4    
  **Cirrhosis**                                                                                                                        
   No                                                                                 138   39.1   12.6      0.303   23.9      11.7    0.268
   Yes                                                                                46    30.4   8.6               17.4      9.9     
  **HBsAg**                                                                                                                            
   Negative                                                                           133   36.8   13.1      0.916   23.3      11.9    0.465
   Positive                                                                           51    37.3   9.5               19.6      9.8     
  **Child-Pugh class**                                                                                                                 
   A                                                                                  164   36.0   11.3      0.272   20.7      9.5     0.148
   B                                                                                  20    45.0   25.0              35.0      16.7    
  **No. of tumors**                                                                                                                    
   Single                                                                             121   43.0   15.3      0.003   28.1      13.8    0.001
   Multiple                                                                           63    25.4   5.5               11.1      6.3     
  **Tumor size (cm)^[a)](#tfn4-crt-2017-106){ref-type="table-fn"}^**                                                                   
   ≤ 6                                                                                97    46.4   17.6      0.006   33.0      16.2    \< 0.001
   \> 6                                                                               87    26.4   7.9               10.3      5.7     
  **Tumor differentiation**                                                                                                            
   Well+moderated                                                                     125   42.4   16.4      0.002   25.6      13.20   0.02
   Poor                                                                               59    25.4   6.1               15.3      7.60    
  **Capsulation**                                                                                                                      
   Noncapsulated                                                                      111   35.1   8.4       0.206   21.6      9.30    0.647
   Capsulated                                                                         73    39.7   17.7              23.3      14.10   
  **Vascular invasion**                                                                                                                
   No                                                                                 173   38.2   13.6      0.112   22.5      12.10   0.114
   Yes                                                                                11    18.2   0.0               18.2      0.0     
  **TNM**                                                                                                                              
   I+II                                                                               79    46.8   18.2      0.002   32.9      19.6    0.003
   III+IV                                                                             105   29.5   6.1               14.3      5.3     
  **Resection margin**                                                                                                                 
   R0                                                                                 108   42.6   20.1      0.001   28.7      17.0    0.001
   R1                                                                                 76    28.9   0.0               13.2      2.60    
  **Lymph node metastasis**                                                                                                            
   No                                                                                 111   43.2   17.7      0.003   29.7      15.5    0.011
   Yes                                                                                73    27.4   3.9               11.0      5.1     
  **Biliary-intestinal anastomosis**                                                                                                   
   No                                                                                 158   38.0   13.0      0.504   23.4      11.2    0.607
   Yes                                                                                26    30.8   13.5              15.4      11.5    
  **Complication**                                                                                                                     
   No                                                                                 155   38.1   12.8      0.389   23.9      11.8    0.127
   Yes                                                                                29    31.0   23.0              13.8      9.2     
  **Intraoperative blood loss (mL)^[a)](#tfn4-crt-2017-106){ref-type="table-fn"}^**                                                    
   ≤ 400                                                                              104   42.3   13.5      0.068   25.0      12.4    0.024
   \> 400                                                                             80    30.0   12.1              18.7      10.0    
  **WBC (×10^9^/L)**                                                                                                                   
   ≤ 10                                                                               148   39.2   13.9      0.214   24.3      11.9    0.088
   \> 10                                                                              36    27.8   10.0              13.9      8.3     
  **Neutrophil (×10^9^/L)^[a)](#tfn4-crt-2017-106){ref-type="table-fn"}^**                                                             
   ≤ 4.55                                                                             93    44.1   17.1      0.034   28.0      13.7    0.031
   \> 4.55                                                                            91    29.7   9.1               16.5      8.8     
  **Platelet (×10^9^/L)**                                                                                                              
   ≤ 300                                                                              139   37.4   13.0      0.754   22.3      11.0    0.963
   \> 300                                                                             45    35.6   14.7              22.2      12.3    
  **AST (U/L)**                                                                                                                        
   ≤ 37                                                                               133   36.1   8.9       0.284   21.1      7.6     0.425
   \> 37                                                                              51    39.2   20.3              25.5      16.3    
  **ALT (U/L)**                                                                                                                        
   ≤ 80                                                                               158   36.7   9.8       0.083   20.3      8.5     0.092
   \> 80                                                                              26    38.5   34.6              34.6      26.9    
  **γ-GT (U/L)**                                                                                                                       
   ≤ 50                                                                               50    48.0   12.3      0.275   28.0      9.9     0.292
   \> 50                                                                              134   32.8   13.5              20.1      10.1    
  **AFP (μg/L)**                                                                                                                       
   ≤ 200                                                                              176   36.9   13.1      0.658   22.7      11.2    0.259
   \> 200                                                                             8     37.5   0.0               12.5      0.0     
  **CEA (μg/L)**                                                                                                                       
   ≤ 5                                                                                107   44.9   17.7      0.008   29.9      13.4    0.001
   \> 5                                                                               77    26.0   6.6               11.7      5.5     
  **CA19-9 (U/mL)**                                                                                                                    
   ≤ 35                                                                               65    43.1   12.0      0.324   24.6      8.3     0.554
   \> 35                                                                              119   33.6   13.9              21.0      11.2    
  **ANRI**                                                                                                                             
   ≤ 6.7                                                                              94    30.9   3.8       0.004   13.8      3.2     0.003
   \> 6.7                                                                             90    43.3   26.6              31.1      20.9    

ICC, intrahepatic cholangiocarcinoma; OS, overall survival; DFS, disease-free survival; HBsAg, hepatitis B surface antigen; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine transaminase; γ-GT, γ-glutamyl transpeptidase; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; ANRI, aspartate aminotransferase/neutrophil count ratio index.

Medians were used for cut-off values.

###### 

Multivariate analyses for independent prognostic factors of patients with ICC (n=184)

  Category                             OS                    DFS                              
  ------------------------------------ --------------------- ---------- --------------------- -------
  Tumor number (single vs. multiple)   1.473 (1.048-2.069)   0.026      \-                    \-
  Tumor size (≤ 6 cm vs. \> 6 cm)      1.408 (1.013-1.959)   0.042      1.725 (1.251-2.380)   0.001
  Tumor differentiation (W+M vs. P)    1.687 (1.202-2.366)   0.002      1.501 (1.078-2.090)   0.016
  Resection margin (R0 vs. R1)         0.556 (0.401-0.770)   \< 0.001   0.580 (0.421-0.800)   0.001
  ANRI (\> 6.7 vs. ≤ 6.7)              0.671 (0.482-0.934)   0.018      0.664 (0.483-0.911)   0.011

Variables with p \< 0.05 calculated by Kaplan-Meier method (log-rank test) were used in multivariate analysis (Cox proportional hazards model, Backward stepwise). ICC, intrahepatic cholangiocarcinoma; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; W+M, well+moderated differentiation; P, poor differentiation; ANRI, aspartate aminotransferase/neutrophil count ratio index.

[^1]: Lingyun Liu and Wei Wang contributed equally to this work.
